About Heptares Therapeutics
Heptares Therapeutics focuses on the discovery and development of novel drugs acting at G-protein coupled receptors (GPCRs). Heptares StaR (Stabilized Receptor) technology enables thermo-stabilization of GPCRs, a breakthrough allowing X-ray crystallography of conformationally-constrained receptors, thereby facilitating structure-based drug design at GPCRs that have been resistant to traditional methods of drug screening.
Heptares Therapeutics Patents
Heptares Therapeutics has filed 105 patents.
Thalamus, Brainstem, Basal ganglia, G protein coupled receptors, Neurophysiology
Thalamus, Brainstem, Basal ganglia, G protein coupled receptors, Neurophysiology
Latest Heptares Therapeutics News
Nov 10, 2023
London, UNITED KINGDOM Tokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and Kallyope, a clinical stage biotechnology company discovering and developing novel, oral small-molecule therapeutics for diseases with high unmet need, today announced the successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal diseases. This is the first scientific milestone stemming from the strategic drug discovery collaboration between the two companies announced in 2022. The collaboration aims to leverage Sosei Heptares’ GPCR Diversified Compound Library and GPCR expertise and the innovative Kallyope Klarity™ platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic screening. The collaborating teams at Sosei Heptares and Kallyope intend to progress the nominated target into a fully supported structure-based drug discovery program as well as continuing to identify additional gastrointestinal targets for future programs. Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, commented: “This first important milestone with Kallyope has been rapidly achieved through the combination of our respective world-leading technologies, expertise and focus on discovering novel therapeutics targeting unmet needs in gastrointestinal diseases. It is exciting to see tangible outputs from our Target Identification and Validation strategy across our portfolio of collaborations with innovative companies, like Kallyope. Advancing novel programs like this into the drug discovery phase is important to enrich our early pipeline and provides opportunities for developing future medicines to address unmet medical need.” “This achievement further confirms the effectiveness of Kallyope’s unique target discovery platform and scientific expertise, and the value of collaboration with the GPCR platform and expertise of Sosei Heptares,” said Jay Galeota, President and CEO, Kallyope. “Our Klarity platform’s broad set of integrated technologies and insights allows us to understand communication between the gut, brain and other organs in a fundamentally new way that, together with the leading compound library and structural biology capabilities that Sosei Heptares has built, can lead to the development of therapeutic interventions that represent important steps forward in treating gastrointestinal diseases, reducing suffering and improving human health.” -ENDS- About Kallyope Kallyope, a clinical stage biotechnology company, is leveraging its proprietary Klarity™ therapeutic platform to discover and develop novel, oral small-molecule therapeutics in areas with high unmet medical need, including diabetes and obesity, gastrointestinal disease, and neurological disorders. About Sosei Heptares Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions. Our global business combines our world-leading GPCR-targeted StaR® technology, structure-based drug design and early development capabilities in the UK with a highly experienced clinical development capability and a commercial operation in Japan. We are leveraging these capabilities to generate and advance a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases. We intend to develop these opportunities for patients in Japan and globally both internally and through our partnerships with global biopharmaceutical companies and emerging technology companies. Sosei Heptares operates from key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea). “Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. For more information, please visit https://soseiheptares.com/
Heptares Therapeutics Frequently Asked Questions (FAQ)
When was Heptares Therapeutics founded?
Heptares Therapeutics was founded in 2007.
Where is Heptares Therapeutics's headquarters?
Heptares Therapeutics's headquarters is located at BioPark, Broadwater Road, Hertfordshire.
What is Heptares Therapeutics's latest funding round?
Heptares Therapeutics's latest funding round is Corporate Minority.
How much did Heptares Therapeutics raise?
Heptares Therapeutics raised a total of $61.17M.
Who are the investors of Heptares Therapeutics?
Investors of Heptares Therapeutics include Teva Pharmaceuticals, Sosei Heptares, Clarus, Takeda Ventures, Stanley Medical Research Institute and 4 more.
Who are Heptares Therapeutics's competitors?
Competitors of Heptares Therapeutics include Carmot Therapeutics, Metabolon, Visiopharm, DiscoverX, KineMed and 7 more.
Compare Heptares Therapeutics to Competitors
Xention is a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs. The Company has potential breakthrough drugs for atrial fibrillation, an area in which it has developed considerable expertise.
Visiopharm is a leading provider of AI-driven precision pathology software, operating in the healthcare and technology sectors. The company's main offerings include software tools for research and diagnostics, which assist scientists, pathologists, and image analysis experts in producing accurate data for all types of tissue-based research, and provide diagnostic decision support for clinical applications. The company primarily serves the healthcare research and diagnostics industries. It was founded in 2001 and is based in Hoersholm, Denmark.
Metabolon is a health technology company that focuses on metabolomics. It offers a tool for precision medicine and life sciences research. The company offers metabolomics solutions for biomarker discoveries, diagnostic tests, and partnerships in genomics-based, health initiatives. Metabolon was founded in 2000 and is based in Morrisville, North Carolina.
Novadrug is a drug discovery company geared toward the identification of effective antimicrobial, antiviral, immunosuppressive and anticancer drugs.
SULFIDRIS, a spin-off of Milan University, is a drug-discovery company. nSULFIDRIS is focused in R&D of drugs (SULFIDRACs) for the treatment of cancer disorders. nSULFIDRACs are multi-modal safe and effective drugs, capable to act on redox-imbalance-related pathogenetic mechanisms.
Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.